

## VU Research Portal

### **Immunogenetics of infection and inflammation of the urogenital and gastrointestinal tracts and probiotics**

Karimi, O.

2011

#### ***document version***

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

#### ***citation for published version (APA)***

Karimi, O. (2011). *Immunogenetics of infection and inflammation of the urogenital and gastrointestinal tracts and probiotics*.

#### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

#### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

#### **E-mail address:**

[vuresearchportal.ub@vu.nl](mailto:vuresearchportal.ub@vu.nl)

## Chapter 11



### **Indications and Challenges of Probiotics, Prebiotics, and Synbiotics in the Management of Arthralgias and Spondyloarthropathies in Inflammatory Bowel Disease**

Ouafae Karimi and Amado Salvador Peña

A compilation of


**Indications and challenges of probiotics, prebiotics and synbiotics in the management of arthralgias and spondyloarthropathies in inflammatory bowel disease**

Karimi O, Peña AS.

and

**Probiotics in arthralgia and spondyloarthropathies in patients with inflammatory bowel disease. Prospective randomized trials are necessary**

Karimi O, Peña AS.



**Abstract**

Arthralgia and spondyloarthropathy of the peripheral and the axial joints are common in patients with inflammatory bowel diseases. Evidence for this association has been provided by clinical, epidemiologic, and immunologic studies confirming the presence of shared inflammatory pathways in gut and joint. Bacterial gut infections such as *Salmonella typhimurium*, *Yersinia enterocolitica*, *Shigella*, *Campylobacter jejuni* may induce reactive peripheral arthritis and 20% of these patients may develop chronic spondyloarthropathy. It is not certain that arthralgias in inflammatory bowel diseases are more frequent than in the general population but clinical articular manifestations compatible with spondyloarthropathy are present in 10% to 40% of patients with inflammatory bowel diseases. These enteropathic peripheral arthropathies without axial involvement are subdivided into a pauciarticular of large joints and a bilateral symmetrical polyarthropathy. The rationale and the challenges of using prebiotics, probiotics, and synbiotics in the management of patients with inflammatory bowel diseases with arthralgias and spondyloarthropathy are briefly reviewed. The rationale is based on the modulation of the ubiquitous intestinal flora by bacteria and their products that have been proven to be safe. The challenge is to find the “window of opportunity” to treat the evolutionary stage of joint inflammation. It seems to us that the major aim is not to treat patients who have a self-limited inflammatory joint disorder, but those patients with persistent arthralgias in an early phase of the disease. Seronegative and seropositive patients with early arthritis, before damage may occur, could be managed by this approach to improve the quality of life and to positively influence the natural course of the disease.

Since a few decades, the concept of spondyloarthropathy (SpA) has evolved into a distinct clinical entity, including axial involvement and peripheral inflammatory arthritis.<sup>1</sup> Typical axial symptoms are low back pain and morning stiffness, alternating buttock pain, decreased mobility of the spine, and impaired thoracic expansion; characteristic radiographic lesions are sacroiliitis and spondylitis. These are the most salient features of ankylosing spondylitis (AS). The peripheral arthritis affects predominantly the large and small joints of the lower limbs in an asymmetric pauciarticular pattern and is frequently associated with an enthesiopathy or inflammation of the insertion of the tendon to the bone. Enteropathic peripheral arthropathy without axial involvement has been subdivided into a pauciarticular large joint arthropathy and a bilateral symmetrical polyarthropathy. Both subgroups can be distinguished by the different distribution of the joint involvement and the natural history of the disease. Patients with recorded joint swelling or effusion were classified as type 1 (pauciarticular) when <5 joints were involved and classified as type 2 (polyarticular) when 5 or more joints were swollen. Patients with joint pain but without evidence of swelling in the joints were classified as suffering from arthralgia.<sup>2</sup>

Another classification on the basis of serologic markers distinguishes 2 groups of SpA. Seronegative spondyloarthritides enclose a group of SpA characterized by the consistent absence of the rheumatoid factor, the involvement of the sacroiliac joints, and by the involvement of peripheral inflammatory arthritis. These SpA are also known as nonerosive and nondeforming arthropathies.<sup>3</sup>

The concept is further characterized by a frequent association with the human leukocyte antigen (HLA)-B27 phenotype and a positive family history of SpA. Several clinical entities belong to this concept: AS, reactive arthritis in patients with a recent history of urogenital or intestinal infection, some forms of psoriasis or psoriatic arthritis or juvenile chronic arthritis, and the extraintestinal articular manifestations of inflammatory bowel disease (IBD). Patients with SpA without being classifiable in one of the clinical entities are defined as undifferentiated SpA.

Next to HLA-B27, other genetic and environmental factors explain the often observed familial aggregation of SpA and IBD.<sup>4-6</sup> Different HLA associations may define phenotypical distinct subgroups.

In this review, we focus on the extraintestinal articular manifestations of IBD, Crohn's disease (CD) and ulcerative colitis (UC), and AS. The relation between SpA and gut inflammation has been confirmed by several studies.<sup>7-9</sup> Two types of inflammation were distinguished: acute inflammation, resembling infectious enterocolitis; and chronic inflammation, more suggestive of early CD.<sup>10</sup> There is increasing genetic and immunologic evidence supporting the clinical and histologic overlap between gut inflammation in SpA and CD. Subclinical gut inflammation was described in several SpA patients.<sup>11,12</sup> Gastrointestinal infections associated with SpA usually involve the terminal ileum and sometimes also the colon, in most cases without joint symptoms.<sup>13,14</sup>

Involvement of the gastrointestinal tract as feature of SpA<sup>15</sup> was found in 25% to 75% of SpA patients.<sup>16</sup> UC and CD are the most frequently encountered types of idiopathic IBD that are associated with SpA. Subclinical inflammatory lesions of the gut can evolve to clinically overt CD. Clinical articular manifestations compatible with SpA are present in up to 39% of patients with IBD.<sup>6</sup> Immunopathologic studies, such as increased E-cadherin/catenin complex expression, have been observed in clinically overt IBD and in subclinically inflamed bowel mucosa from SpA patients.<sup>17,18</sup>

### ***Mechanisms of action of pre-, pro- and synbiotics in arthralgia and SPA in IBD***

Recently, focus has been placed on prebiotic, probiotic, and synbiotic therapies, which aim to restore balance to the gastrointestinal microbiota and reduce intestinal inflammation. However, a greater understanding of the mechanisms behind their action on the gastrointestinal

microbiota is required to determine which prebiotic, probiotic, or synbiotic is the most beneficial.<sup>19</sup> Probiotics are live microbial feed supplements, which benefit the host by improving its intestinal microbial balance and probably complement the normal nutrition.<sup>20</sup> Although the full mechanisms of action are still unclear, proven beneficial activities are (1) inhibition of pathogenic bacterial growth or epithelial attachment preventing invasion, (2) improvement of the epithelial barrier function, (3) promoting homeostatic immunoregulation by the induction of interleukin (IL)-10, transforming growth factor (TGF)- $\beta$  and by the inhibition of tumor necrosis factor (TNF)- $\alpha$  and IL-12 synthesis,<sup>21</sup> and (4) inhibition of the p38 mitogenactivated protein kinase (MAPK) pathway.<sup>22</sup> The “p38 MAPK” is a mediator of endotoxin-induced production of cyclooxygenase-2 (COX2) in enterocytes.<sup>23</sup>

### ***Inhibition of Pathogenic Bacterial Growth or Epithelial Attachment Preventing Invasion***

Several studies have suggested a link between gramnegative enterobacteria and IBD.<sup>24,25</sup> The involvement of *Yersinia* and *Salmonella* in reactive arthritis, as well as *Shigella* and *Campylobacter* spp. and *Klebsiella* was reported.<sup>25,26</sup> The observations of Orchard and Jewell<sup>27</sup> are consistent with the hypothesis that luminal bacteria in this region are important in the pathogenesis of reactive arthritis. They compared a group of CD patients with ileocecal resection with a group of CD patients without ileocecal resection. Patients who underwent an ileocecal resection, presented fewer arthritic complications.<sup>27</sup>

### ***Improvement of the epithelial barrier function***

An important feature of CD is the impairment of the integrity of the epithelial barrier. Evidence shows an increased exposure to foreign antigens suggesting a possible link between increase in intestinal permeability and antigenic penetration. This is based on the observation that proinflammatory cytokines, such as TNF- $\alpha$  and IL-13, induce epithelial apoptosis in TH2 immune responses and thereby upregulate the apoptotic rate and single apoptotic conductivity both in UC and CD.<sup>28</sup> Patients with seronegative SpA, even in the absence of gastrointestinal symptoms, showed evidence of gut inflammation, probably inducing an increased gut permeability with transgression of the oral tolerance and absorption of provocative antigens into the circulation.<sup>7</sup> In IBD and SpA, there is a polygenic predisposition and a high prevalence of increased intestinal permeability.<sup>29–32</sup>

***Effects on adhesion molecules***

E-cadherin, an adhesion molecule, seems to play an important role in the barrier integrity by mediating homotypic, homophilic intercellular adhesion in epithelial cells. As was shown by Demetter et al<sup>18</sup> in clinical IBD, it seems to be upregulated in active inflammation. Because structural or functional perturbation in any of the molecules of the E-cadherin–catenin complex results in loss of intercellular adhesion, the preexistent epithelium may benefit from upregulation to try to maintain its normal architecture under inflammatory conditions. In acute and chronic active bowel inflammation of SpA patients, upregulation of the E-cadherin/catenin glycoprotein complex was observed. Chronic lesions in a quiescent state did not show such an upregulation, whereas chronic inflammation was associated with an increase in E-cadherin mRNA. As some of the SpA patients with subclinical gut inflammation develop IBD, upregulation of the E-cadherin/catenin complex in inflamed bowel mucosa from SpA patients may point to early cellular changes in the development of IBD and, thereby mimicking the situation in CD.<sup>17</sup>

***Promotion of homeostatic immunoregulation by the induction IL-10, TGF- $\beta$ , and by the inhibition of TNF- $\alpha$  and IL-12 synthesis***

E-cadherin is also a ligand for the  $\alpha$ E $\beta$ 7 integrin on intraepithelial T cells. Therefore, changes may also play a role in the homing of specific T-lymphocyte populations in SpA gut mucosa. Phenotypic characterization of IL-2 expanded T-cell lines (CD3 and CD8) from mucosal biopsies showed upregulated  $\alpha$  E $\beta$ 7 expression in CD.<sup>33,34</sup> A similar upregulation of  $\alpha$ E $\beta$ 7 in AS demonstrated that similar T-cell populations may be present in the bowel in both diseases.<sup>35</sup> Interestingly, a differential expression of the integrins  $\alpha$  E $\beta$ 7 and  $\alpha$  4 $\beta$ 7 on synovium-derived T-cell lines in SpA was seen, whereas one of the ligands of  $\alpha$ 4 $\beta$ 7, VCAM-1, is highly expressed in SpA synovium.<sup>33,36</sup> An impaired TH1 cytokine profile is observed in gut mucosal lymphocytes from patients with SpA. The mucosal T-cell populations in CD and AS were functionally characterized with regard to the TH1/TH2 cytokine profile. Analyzing the percentage of cytokine-producing cells, there was a global predominance of interferon- $\gamma$  and IL-2 compared with IL-4 and IL-10 in both conditions. However, in colon lamina propria lymphocytes in both SpA and CD, a proportional decrease of IFN- $\gamma$  and IL-2 producing CD3 and CD3<sup>+</sup>CD8<sup>-</sup> lymphocytes was observed compared with the control situation, suggesting a relative impairment of TH1 cytokine production.<sup>37,38</sup>

### *Effects on dendritic cells and macrophages*

Macrophages expressing CD163 were found to be increased in colonic mucosa in SpA and in CD, stressing the relationship between these entities. The increased number of CD163<sup>+</sup> macrophages in colon mucosa of patients with SpA suggests that this is another argument for a role of macrophage scavenger receptors in this group of diseases. Based on these observations, the hypothesis is that the mucosal immune system may be abnormally exposed to bacterial antigens in AS, leading to specific T-cell reactivity. Therefore, the immune cells involved in antigen handling and presentation in gut mucosa from patients with SpA and CD were further investigated using a similar immunohistochemical approach.<sup>39</sup> Patients with SpA and CD were associated with large numbers of CD68<sup>+</sup> macrophages, whereas there were no prominent alterations in dendritic cell populations.

The colons of SpA patients and CD patients, but not UC patients, showed increased numbers of macrophages expressing the scavenger receptor CD163. Among the immune alterations, an increased number of the macrophage scavenger receptor CD163 was found in the synovium and colonic mucosa of SpA patients.<sup>40-42</sup> These findings highlight the presence of early immune alterations in the SpA gut mucosa that are reminiscent of CD, and suggest that macrophage populations and, more generally, the innate immune system, rather than acquired immunity, may be involved in the inflammatory process in AS.

### *Inhibition of the p38 MAPK Pathway*

Inflammatory molecules such as COX2 are important.<sup>23</sup> The modulation of COX2 expression is an important mechanism of the anti-inflammatory and anticarcinogenic property of some probiotics.<sup>43</sup> The probiotic *Lactobacillus rhamnosus* GG was found to induce COX2 expression in human T84 colon epithelial cells.<sup>44</sup> Recently, a MAPK called p38 has been reported to act as a mediator in the endotoxin-induced production of COX2 in enterocytes.<sup>23</sup> The inhibition of the p38 MAPK pathway may inhibit the COX2 expression. This is relevant because previous studies have shown that probiotic bacteria inhibit the p38 MAPK pathway.<sup>22</sup> We, therefore, hypothesize that the link p38 and COX2 may explain the beneficial effect of probiotics in the treatment of arthralgia, because probiotic bacteria inhibit this pathway and have a role in preventing intestinal cancer. In acute and chronic active bowel inflammation of SpA patients, E-cadherin mRNA is upregulated.<sup>17</sup>

Because E-cadherin is also a ligand for the  $\alpha E\beta 7$  integrin on intraepithelial T cells, it may play a role in the homing of specific T-lymphocyte populations to the gut mucosa. As some of the SpA patients with subclinical gut inflammation develop IBD, upregulation of the E-cadherin/ catenin complex in inflamed bowel mucosa from SpA patients may point to early cellular changes in the development of IBD and thereby mimicking the situation in CD.<sup>17</sup>

***Effect on the innate immune system***

Other immune alterations found in the synovium and colonic mucosa of SpA patients are an increased number of the macrophage scavenger receptor CD163.<sup>40</sup> These findings demonstrate that the innate immune system rather than the acquired immunity may be involved in the inflammatory process of early arthritis. Prebiotics have several proposed mechanisms of action, including the enhancement of luminal concentrations of endogenous Lactobacilli spp. and Bifidobacterium spp.

Prebiotics, probiotics, and synbiotics stimulate the production of short chain fatty acids, particularly butyrate enhancing the water-holding capacity of the stool.<sup>21</sup>

***Influence of the genetic factors and expression***

According to Orchard *et al*<sup>45</sup> pauciarticular arthropathy (type 1) is clinically and immunogenetically similar to the manifestations of SpA. According to these authors, different HLA associations may define phenotypically distinct subgroups. In IBD and SpA, there is a polygenic predisposition and a high prevalence of increased intestinal permeability.<sup>29-32</sup> Endoscopy and histology of ileal biopsy specimens have shown a high prevalence of asymptomatic intestinal inflammation in patients with assumed idiopathic AS (chronic SpA) with or without the HLA-B27 marker.<sup>8,10,24</sup>

SpA patients with subclinical chronic gut inflammation were found to cluster with CD patients by means of expression of 95 genes.<sup>46</sup> Among these genes 2 genes were already described in the context of CD: acylcoenzyme A oxidase, whose activity was strongly reduced in patients with CD; and glutathione peroxidase 2, exclusively expressed in the intestine and over expressed in the normal colonic tissue of CD patients and SpA patients with chronic gut inflammation.<sup>47,48</sup> This suggests that some of these genes can act as an early genetic marker for evolution to CD in SpA patients.<sup>46</sup>

***Common immunologic mechanisms***

Immunohistochemical studies in mucosal biopsy specimens of SpA patients also showed an increase of immunoglobulin-containing cells, similar to CD and UC.<sup>49</sup> This suggests that gut inflammation is linked to peripheral joint disease in AS and SpA, raising the question of common immunologic and inflammatory pathways in these 2 distinct organ manifestations. The gut-joint recirculation of lymphocytes was supported by the identification of identical T-cell expansions in both the colon mucosa and the synovium of a patient with enterogenic SpA.<sup>50</sup> Gut-derived lymphocytes from IBD patients were shown to bind to synovial vessels using multiple homing receptors and their corresponding endothelial ligands, including



R1 vascular adhesion protein-1.<sup>51</sup> Moreover, analysis of synovial fluid T cells and synovial  
R2 membrane specimens in SpA and rheumatoid arthritis confirmed that the decreased TH1  
R3 (IFN-g)/TH2 (IL-4) ratio also extended to the joints of SpA patients.<sup>52,53</sup> This confirms the  
R4 concept that a defective TH1 response at the mucosal site may impair the immune defense  
R5 against intracellular bacteria and thereby contribute to a decreased immune tolerance against  
R6 bacterial antigens.

R7 Paralleling the observations in the gut, low secretion of IFN-g, IL-2, and/or TNF-a and an  
R8 increase in IL-10 production by T cells were also reported in the peripheral blood of patients  
R9 with several types of SpA.<sup>54-56</sup> Similar expression of T lymphocyte adhesion molecules and  
R10 their ligands and a similar functional behavior (impaired TH1/TH2 profile) further underscore  
R11 the immunologic link between joints and the gut in AS and SpA.

R12 Bacterial persistence could lead to tissue inflammation by direct stimulation of inflammatory  
R13 cells such as monocytes, macrophages, and neutrophils, but also intestinal epithelial cells. In  
R14 general, innate immune cells such as macrophages recognize microbial pathogen-associated  
R15 molecular patterns through their toll-like receptors (TLRs) and initiate a rapid and quite  
R16 nonspecific innate immune response upon TLR triggering. After binding of bacterial  
R17 lipoproteins (TLR2), endotoxins (TLR4), flagellin (TLR5), bacterial CpG dinucleotides  
R18 (TLR9) or bacterial heat shock proteins, the TLRs in association with the adapter molecule  
R19 MyD88 initiate a signaling cascade resulting in the activation of NF- $\kappa$ B and the induction  
R20 of oxidative stress, the production of inflammatory cytokines, and apoptosis. In IBD and  
R21 SpA, there is evidence of an abnormal expression of TLRs on gastrointestinal epithelial cells  
R22 in IBD.<sup>57</sup> TLR2 and TLR4, showing an increased expression on the CD163<sup>+</sup> macrophages,  
R23 are also significantly increased in SpA synovium compared with rheumatoid arthritis  
R24 synovium.<sup>58</sup> Treatment in vivo with TNF-a blockers leads to a significant reduction of the  
R25 abnormal TLR expression on these cells, which was functionally paralleled by a decreased  
R26 production of proinflammatory cytokines upon lipopolysaccharide triggering but not upon  
R27 TLR independent stimulation. Together with the role for nucleotide-binding oligomerization  
R28 domain containing 2/ caspase recruitment domain family, member 15 in SpA, the concept  
R29 that the combination of microbial triggering and an abnormal inflammatory response of the  
R30 innate immune system in genetically susceptible hosts can lead to a breakdown of the normal  
R31 immunologic tolerance and to a pathogenic cellular immune response to specific bacterial  
R32 species and/or cross-reacting self-molecules is supported. As indicated, this may lead to a  
R33 disturbed balance between proinflammatory cytokines such as TNF- $\alpha$  and anti-inflammatory  
R34 cytokines such as IL-10, which may ultimately result in inflammation in the gut and the joint.  
R35  
R36  
R37  
R38  
R39

***The role of pre- and probiotics in SpA***

Non-steroidal anti-inflammatory drugs (NSAIDs) are the mainstay of medical therapy in AS and are recommended as first-line therapy in all AS patients.<sup>59</sup> However, NSAID therapy in AS patients with concomitant IBD may have deleterious effects on IBD. There are numerous reports on patients without AS suggesting that NSAIDs exacerbate IBD or reactivate preexisting IBD.<sup>60–63</sup>

Prebiotics are dietary substances, mostly nondigested carbohydrates, which promote the growth and metabolic activity of beneficial enteric bacteria. Prebiotics have been studied less extensively; however, they may become an ideal treatment or cotreatment option because of their capacity to increase endogenous lactobacillus and bifidobacteria. Combined probiotics and prebiotics (synbiotics) can restore a predominance of beneficial *Lactobacillus* and *Bifidobacterium* spp.; however, as far as we know no studies have been performed in IBD patients with arthralgia. We have undertaken a proof-of-concept study to determine the safety and efficacy of probiotics in patients with quiescent IBD who suffered from arthralgia for more than 2 weeks. The results suggest that VSL# 3 may be an alternative treatment for arthralgia in patients with IBD.<sup>64,65</sup>

Probiotics differ in the modulation of the intestinal inflammatory response. Although the safety of probiotics containing lactobacilli and bifidobacteria has been evaluated critically and probiotics were considered to be at least as safe as appropriate traditional reference food,<sup>66</sup> one has to take into consideration that not all probiotic bacteria have similar therapeutic effects as stated earlier. Prebiotics have several proposed mechanisms of action, including the enhancement of luminal concentrations of endogenous *Bifidobacterium* spp., stimulating production of short chain fatty acids, particularly butyrate, and enhancing water-holding capacity of the stool.<sup>21</sup>

***The future***

Future research in this field needs to focus on determining which probiotics are the most efficacious in patients with arthritis, SpA, and IBD. How the genetic and bacterial profiles of the patient will influence treatment responsiveness. In this direction an interesting study has been published. A glass-based microarray, based on the identification of 2625 expressed sequence tags that are differentially expressed in the colon of patients with CD or SpA was used to analyze colon biopsy specimens from 15 patients with SpA, 11 patients with CD, and 10 controls. The genes expressed from patients with SpA with subclinical chronic gut inflammation, cluster together and are more related to those with CD than the controls. This result suggests that some of these genes can act as an early genetic marker for evolution to CD in SpA patients.<sup>46</sup>

## Conclusions

On the basis of the results of the experimental animal models, the concepts described in this review and our preliminary clinical observations, we believe that the use of probiotics may be effective in the management of patients with IBD suffering from arthralgia and/or SpA. Controlled randomized clinical trials to investigate the as yet unresolved issues with regard to efficacy, dose, and duration of use and/or single or multistrain formulation are necessary to prove this beneficial effect. A major challenge at present is to find markers to be able to identify those patients in the early phase of the disease.

R1  
R2  
R3  
R4  
R5  
R6  
R7  
R8  
R9  
R10  
R11  
R12  
R13  
R14  
R15  
R16  
R17  
R18  
R19  
R20  
R21  
R22  
R23  
R24  
R25  
R26  
R27  
R28  
R29  
R30  
R31  
R32  
R33  
R34  
R35  
R36  
R37  
R38  
R39

## References

1. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. *Arthritis Rheum.* 1991;34: 1218–1227.
2. Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. *Gut.* 1998;42:387–391.
3. Gravallesse EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. *Am J Gastroenterol.* 1988;83:703–709.
4. Gonzalez S, Garcia-Fernandez S, Martinez-Borra J, et al. High variability of HLA-B27 alleles in ankylosing spondylitis and related spondyloarthropathies in the population of northern Spain. *Hum Immunol.* 2002;63:673–676.
5. Brophy S, Pavy S, Lewis P, et al. Inflammatory eye, skin, and bowel disease in spondyloarthritis: genetic, phenotypic, and environmental factors. *J Rheumatol.* 2001;28:2667–2673.
6. de Vlam K, Mielants H, Cuvelier C, et al. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. *J Rheumatol.* 2000;27:2860–2865.
7. De Vos M, Cuvelier C, Mielants H, et al. Ileocolonoscopy in seronegative spondylarthropathy. *Gastroenterology.* 1989;96(2 Pt 1):339–344.
8. Mielants H, Veys EM, Cuvelier C, et al. HLA-B27 related arthritis and bowel inflammation. Part 2. Ileocolonoscopy and bowel histology in patients with HLA-B27 related arthritis. *J Rheumatol.* 1985;12:294–298.
9. Mielants H, Veys EM, Goemaere S, et al. Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study. *J Rheumatol.* 1991;18:1542–1551.
10. Cuvelier C, Barbatis C, Mielants H, et al. Histopathology of intestinal inflammation related to reactive arthritis. *Gut.* 1987;28: 394–401.
11. Mielants H, Veys EM, Cuvelier C, et al. Gut inflammation in children with late onset pauciarticular juvenile chronic arthritis and evolution to adult spondyloarthropathy—a prospective study. *J Rheumatol.* 1993;20:1567–1572.
12. Schatteman L, Mielants H, Veys EM, et al. Gut inflammation in psoriatic arthritis: a prospective ileocolonoscopy study. *J Rheumatol.* 1995;22:680–683.
13. Leirisalo-Repo M, Turunen U, Stenman S, et al. High frequency of silent inflammatory bowel disease in spondylarthropathy. *Arthritis Rheum.* 1994;37:23–31.
14. Smale S, Natt RS, Orchard TR, et al. Inflammatory bowel disease and spondylarthropathy. *Arthritis Rheum.* 2001;44:2728–2736.

- R1  
R2  
R3  
R4  
R5  
R6  
R7  
R8  
R9  
R10  
R11  
R12  
R13  
R14  
R15  
R16  
R17  
R18  
R19  
R20  
R21  
R22  
R23  
R24  
R25  
R26  
R27  
R28  
R29  
R30  
R31  
R32  
R33  
R34  
R35  
R36  
R37  
R38  
R39
15. De Keyser F, Elewaut D, De Vos M, et al. Bowel inflammation and the spondyloarthropathies. *Rheum Dis Clin North Am.* 1998;24: 785–813, ix-x.
16. De Vos M, Mielants H, Cuvelier C, et al. Long-term evolution of gut inflammation in patients with spondyloarthropathy. *Gastroenterology.* 1996;110:1696–1703.
17. Demetter P, Baeten D, De Keyser F, et al. Subclinical gut inflammation in spondyloarthropathy patients is associated with upregulation of the E-cadherin/catenin complex. *Ann Rheum Dis.* 2000;59:211–216.
18. Demetter P, De Vos M, Van Damme N, et al. Focal up-regulation of E-cadherin-catenin complex in inflamed bowel mucosa but reduced expression in ulcer-associated cell lineage. *Am J Clin Pathol.* 2000;114:364–370.
19. Geier MS, Butler RN, Howarth GS. Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. *Int J Food Microbiol.* 2007;115:1–11.
20. Berg RD. Probiotics, prebiotics or “conbiotics”? *Trends Microbiol.* 1998;6:89–92.
21. Balfour Sartor R. Bacteria in Crohn’s disease: mechanisms of inflammation and therapeutic implications. *J Clin Gastroenterol.* 2007;41(5 suppl 1):S37–S43.
22. Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. *J Biol Chem.* 2002;277:50959–50965.
23. Grishin A, Wang J, Hackam D, et al. p38MAP kinase mediates endotoxin-induced expression of cyclooxygenase-2 in enterocytes. *Surgery.* 2004;136:329–335.
24. Leirisalo-Repo M, Repo H. Gut and spondyloarthropathies. *Rheum Dis Clin North Am.* 1992;18:23–35.
25. Hermann E, Yu DT, Meyer zum Buschenfelde KH, et al. HLA-B27-restricted CD8T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. *Lancet.* 1993;342:646–650.
26. Mattila L, Leirisalo-Repo M, Koskimies S, et al. Reactive arthritis following an outbreak of Salmonella infection in Finland. *Br J Rheumatol.* 1994;33:1136–1141.
27. Orchard TR, Jewell DP. The importance of ileocaecal integrity in the arthritic complications of Crohn’s disease. *Inflamm Bowel Dis.* 1999;5:92–97.
28. Schulzke JD, Bojarski C, Zeissig S, et al. Disrupted barrier function through epithelial cell apoptosis. *Ann N Y Acad Sci.* 2006;1072:288–299.
29. Holden W, Orchard T, Wordsworth P. Enteropathic arthritis. *Rheum Dis Clin North Am.* 2003;29:513–530, viii.
30. Mielants H, Veys EM, Cuvelier C, et al. Ileocolonoscopy findings in seronegative spondylarthropathies. *Br J Rheumatol.* 1988;27(suppl 2):95–105.
31. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: an overview. *Gastroenterology.* 1995;108:1566–1581.

32. Martinez-Gonzalez O, Cantero-Hinojosa J, Paule-Sastre P, et al. Intestinal permeability in patients with ankylosing spondylitis and their healthy relatives. *Br J Rheumatol.* 1994;33:644–647.
33. Elewaut D, De Keyser F, Van Den Bosch F, et al. Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. *J Rheumatol.* 1998;25:1932–1937.
34. Elewaut D, De Keyser F, Cuvelier C, et al. Distinctive activated cellular subsets in colon from patients with Crohn’s disease and ulcerative colitis. *Scand J Gastroenterol.* 1998;33:743–748.
35. Van Damme N, Elewaut D, Baeten D, et al. Gut mucosal T cell lines from ankylosing spondylitis patients are enriched with alphaEbeta7 integrin. *Clin Exp Rheumatol.* 2001;19:681–687.
36. Baeten D, Kruithof E, Van den Bosch F, et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study. *Arthritis Rheum.* 2001;44:186–195.
37. Van Damme N, De Keyser F, Demetter P, et al. The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome. *Clin Exp Immunol.* 2001;125:383–390.
38. Van Damme N, De Vos M, Baeten D, et al. Flow cytometric analysis of gut mucosal lymphocytes supports an impaired Th1 cytokine profile in spondyloarthropathy. *Ann Rheum Dis.* 2001;60:495–499.
39. Demetter P, De Vos M, Van Huysse JA, et al. Colon mucosa of patients both with spondyloarthritis and Crohn’s disease is enriched with macrophages expressing the scavenger receptor CD163. *Ann Rheum Dis.* 2005;64:321–324.
40. Baeten D, Demetter P, Cuvelier CA, et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. *J Pathol.* 2002;196:343–350.
41. Baeten D, Demetter P, Cuvelier C, et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. *Ann Rheum Dis.* 2000;59:945–953.
42. Smeets TJ, Dolhain RJ, Breedveld FC, et al. Analysis of the cellular infiltrates and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis. *J Pathol.* 1998;186:75–81.
43. Nurmi JT, Puolakkainen PA, Rautonen NE. Bifidobacterium Lactis sp. 420 Up-Regulates Cyclooxygenase (Cox)-1 and Down-Regulates Cox-2 Gene Expression in a Caco-2 Cell Culture Model. *Nutr Cancer.* 2005;51:83–92.

R1  
R2  
R3  
R4  
R5  
R6  
R7  
R8  
R9  
R10  
R11  
R12  
R13  
R14  
R15  
R16  
R17  
R18  
R19  
R20  
R21  
R22  
R23  
R24  
R25  
R26  
R27  
R28  
R29  
R30  
R31  
R32  
R33  
R34  
R35  
R36  
R37  
R38  
R39

- R1  
R2  
R3  
R4  
R5  
R6  
R7  
R8  
R9  
R10  
R11  
R12  
R13  
R14  
R15  
R16  
R17  
R18  
R19  
R20  
R21  
R22  
R23  
R24  
R25  
R26  
R27  
R28  
R29  
R30  
R31  
R32  
R33  
R34  
R35  
R36  
R37  
R38  
R39
44. Korhonen R, Kosonen O, Korpela R, et al. The expression of COX2 protein induced by *Lactobacillus rhamnosus* GG, endotoxin and lipoteichoic acid in T84 epithelial cells. *Lett Appl Microbiol.* 2004;39:19–24.
45. Orchard TR, Thiyagaraja S, Welsh KI, et al. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. *Gastroenterology.* 2000;118:274–278.
46. Laukens D, Peeters H, Cruyssen BV, et al. Altered gut transcriptome in spondyloarthropathy. *Ann Rheum Dis.* 2006;65: 1293–1300.
47. Aimone-Gastin I, Cable S, Keller JM, et al. Studies on peroxisomes of colonic mucosa in Crohn's disease. *Dig Dis Sci.* 1994;39:2177–2185.
48. Tuzun A, Erdil A, Inal V, et al. Oxidative stress and antioxidant capacity in patients with inflammatory bowel disease. *Clin Biochem.* 2002;35:569–572.
49. Cuvelier C, Mielants H, De Vos M, et al. Immunoglobulin containing cells in terminal ileum and colorectum of patients with arthritis related gut inflammation. *Gut.* 1988;29:916–925.
50. May E, Marker-Hermann E, Wittig BM, et al. Identical T-cell expansions in the colon mucosa and the synovium of a patient with enterogenic spondyloarthropathy. *Gastroenterology.* 2000;119:1745–1755.
51. Salmi M, Jalkanen S. Human leukocyte subpopulations from inflamed gut bind to joint vasculature using distinct sets of adhesion molecules. *J Immunol.* 2001;166:4650–4657.
52. Yin Z, Siegert S, Neure L, et al. The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. *Rheumatology (Oxford).* 1999;38:1058–1067.
53. Canete JD, Martinez SE, Farres J, et al. Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies. *Ann Rheum Dis.* 2000;59:263–268.
54. Yin Z, Braun J, Neure L, et al. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. *Arthritis Rheum.* 1997;40:1788–1797.
55. Baeten D, Van Damme N, Van den Bosch F, et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. *Ann Rheum Dis.* 2001;60:750–755.
56. Rudwaleit M, Siegert S, Yin Z, et al. Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. *Ann Rheum Dis.* 2001;60:36–42.

57. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. *Infect Immun.* 2000;68:7010–7017.
58. De Rycke L, Vandooren B, Kruithof E, et al. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. *Arthritis Rheum.* 2005;52:2146–2158.
59. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Ann Rheum Dis.* 2006;65:442–452.
60. Rampton DS, Sladen GE. Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs. *Postgrad Med J.* 1981;57:297–299.
61. Felder JB, Korelitz BI, Rajapakse R, et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a casecontrol study. *Am J Gastroenterol.* 2000;95:1949–1954.
62. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. *Ann Intern Med.* 1987; 107:513–516.
63. Cipolla G, Crema F, Sacco S, et al. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. *Pharmacol Res.* 2002;46:1–6.
64. Karimi O, Peña AS. Probiotics: isolated bacteria strain or mixtures of different strains? Two different approaches in the use of probiotics as therapeutics. *Drugs Today (Barc).* 2003;39:565–597.
65. Karimi O, Peña AS. Probiotics in arthralgia and spondyloarthropathies in patients with inflammatory bowel disease. Prospective randomized trials are necessary. *Rev Esp Enferm Dig.* 2005;97: 570–574.
66. Borriello SP, Hammes WP, Holzapfel W, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. *Clin Infect Dis.* 2003; 36:775–780.

R1  
R2  
R3  
R4  
R5  
R6  
R7  
R8  
R9  
R10  
R11  
R12  
R13  
R14  
R15  
R16  
R17  
R18  
R19  
R20  
R21  
R22  
R23  
R24  
R25  
R26  
R27  
R28  
R29  
R30  
R31  
R32  
R33  
R34  
R35  
R36  
R37  
R38  
R39